ChemoCentryx, Vifor expand alliance to include CCX140 to treat renal diseases
Vifor Pharma, a company of the Galenica Group, and ChemoCentryx announced the expansion of their existing kidney health alliance to include the development and commercialization of CCX140, an orally-administered inhibitor of the chemokine receptor known as CCR2, for renal diseases. CCX140 has previously completed a successful Phase II clinical trial in patients with diabetic kidney disease. The alliance will initially focus on the joint development of CCX140 in rare kidney diseases, with Vifor Pharma retaining an option to solely develop and commercialize CCX140 in more prevalent forms of chronic kidney disease. Under the agreement, ChemoCentryx retains marketing rights for rare renal disease in the U.S. and China, while Vifor Pharma has commercialization rights in the rest of the world. Under the terms of the agreement, ChemoCentryx will receive an upfront cash payment of $50M. In addition, ChemoCentryx will be eligible to receive additional payments upon the achievement of certain development, regulatory and sales-based milestones, as well as tiered double-digit royalties on net sales of CCX140 in the licensed territories. ChemoCentryx will be responsible for the clinical development of CCX140 in rare renal diseases, while sharing the cost of such development with Vifor Pharma. Should Vifor Pharma later exercise the CKD option, Vifor Pharma would then be responsible for all development and would receive worldwide rights to CCX140, while ChemoCentryx would receive co-promotion rights in CKD in the U.S.